Cryoport (CYRX) Aktievy
Cryoport, Inc. tillhandahåller temperaturkontrollerade lösningar för leveranskedjor på marknaderna för biopharma/pharma, djurhälsa och reproduktionsmedicin över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
CYRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cryoport, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$17.13 |
| 52 veckors högsta | US$17.20 |
| 52 veckors lägsta | US$7.61 |
| Beta | 1.89 |
| 1 månads förändring | 11.45% |
| 3 månaders förändring | 22.71% |
| 1 års förändring | 94.44% |
| 3 års förändring | 22.10% |
| 5 års förändring | -72.83% |
| Förändring sedan börsintroduktionen | -84.57% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 23
CYRX: Cell And Gene Recovery And Bioservices Edge Will Support Future Repricing
Analysts have raised their blended price target for Cryoport to about $19.33 from roughly $17.06, citing updated views on revenue growth, profit margins, and future P/E, following a series of Street target increases ranging from $13.50 to $25. Analyst Commentary Recent Street research on Cryoport points to a more constructive tone on the stock, with several bullish analysts lifting price targets after revisiting their views on the company’s growth drivers and execution in core segments like Cell and Gene Therapy logistics and bioservices.
Uppdatering av berättelse • Aug 09
CYRX: Cell And Gene Therapy Recovery Will Test Service Margin Resilience
Cryoport's updated analyst price target has moved from $12.00 to $15.00 as analysts point to improving growth expectations across cell and gene therapy exposure, a higher assumed future P/E, and more confidence in the quality and visibility of the company’s services businesses. Analyst Commentary Recent research on Cryoport highlights a cluster of higher price targets that sit above the updated US$15 reference point.Recent updates
Uppdatering av berättelse • Aug 23
CYRX: Cell And Gene Recovery And Bioservices Edge Will Support Future Repricing
Analysts have raised their blended price target for Cryoport to about $19.33 from roughly $17.06, citing updated views on revenue growth, profit margins, and future P/E, following a series of Street target increases ranging from $13.50 to $25. Analyst Commentary Recent Street research on Cryoport points to a more constructive tone on the stock, with several bullish analysts lifting price targets after revisiting their views on the company’s growth drivers and execution in core segments like Cell and Gene Therapy logistics and bioservices.Uppdatering av berättelse • Aug 09
CYRX: Cell And Gene Therapy Recovery Will Test Service Margin Resilience
Cryoport's updated analyst price target has moved from $12.00 to $15.00 as analysts point to improving growth expectations across cell and gene therapy exposure, a higher assumed future P/E, and more confidence in the quality and visibility of the company’s services businesses. Analyst Commentary Recent research on Cryoport highlights a cluster of higher price targets that sit above the updated US$15 reference point.Uppdatering av berättelse • Jul 26
CYRX: Cell And Gene Recovery And Bioservices Differentiation Will Support Balanced Outlook
Cryoport's analyst price target has been revised higher from $15.61 to $17.06 as analysts factor in improving conditions in cell and gene therapy markets, healthier growth across MVE, BioLogistics and BioStorage, and more durable bioservices demand. Analyst Commentary Recent Street research on Cryoport points to a more constructive tone around the stock, with several price target increases anchored to what analysts see as improving execution across cell and gene therapy support, MVE, and bioservices operations.Uppdatering av berättelse • Jul 10
CYRX: External Funding And Regulatory Dependence Will Constrain Service Margin Upside
Analysts have raised the fair value estimate for Cryoport stock from $11.00 to $12.00, citing higher price targets across the Street as they emphasize durable bioservices demand, stronger revenue visibility, and supportive regulatory and funding conditions. Analyst Commentary Recent research on Cryoport centers on how durable bioservices demand, regulatory conditions, and funding trends may influence the stock's risk and reward profile.
Uppdatering av berättelse • Jun 26
CYRX: Bioservices Demand And Service Mix Will Drive Future Upside
The analyst price target for Cryoport has been raised from $16.00 to about $19.93. Analysts cite stronger expected revenue growth, slightly higher margin assumptions, and a modestly lower future P/E multiple as key factors behind their updated view.Uppdatering av berättelse • Jun 12
CYRX: Differentiated Bioservices And Regulatory Support Will Shape Balanced Forward Outlook
Cryoport's analyst price target has moved up by $2 to $15.61, with analysts pointing to stronger appreciation for its differentiated bioservices offering, higher perceived revenue visibility and margin potential, and ongoing regulatory and funding support for growth as key drivers of their updated views. Analyst Commentary Recent research updates have centered on Cryoport's bioservices operations, with several firms revisiting their valuation frameworks after site visits and a review of end market conditions.Uppdatering av berättelse • May 29
CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution
Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.Uppdatering av berättelse • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.Uppdatering av berättelse • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.Uppdatering av berättelse • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.Uppdatering av berättelse • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.Uppdatering av berättelse • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).Uppdatering av berättelse • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).Uppdatering av berättelse • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).Uppdatering av berättelse • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.Uppdatering av berättelse • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.Uppdatering av berättelse • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.Uppdatering av berättelse • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.Uppdatering av berättelse • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.Uppdatering av berättelse • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.Uppdatering av berättelse • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.Analysartikel • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...Analysartikel • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...Analysartikel • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Ny berättelse • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Analysartikel • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...Analysartikel • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...Analysartikel • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...Aktieägarnas avkastning
| CYRX | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 11.8% | 7.1% | -1.2% |
| 1Y | 94.4% | 25.7% | 18.3% |
Avkastning vs industri: CYRX översteg US Life Sciences branschen som gav 25.7 % under det senaste året.
Avkastning vs Marknaden: CYRX översteg US marknaden som gav 18.3 % under det senaste året.
Prisvolatilitet
| CYRX volatility | |
|---|---|
| CYRX Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: CYRX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: CYRX s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1999 | 688 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. tillhandahåller temperaturkontrollerade supply chain-lösningar inom biopharma/pharma, djurhälsa och reproduktionsmedicin över hela världen. Bolagets segment Life Sciences Services tillhandahåller temperaturkontrollerad logistik och biostorage, bioservice och kryokonserveringstjänster inom life science-industrin. Segmentet Life Sciences Products tillverkar och säljer kryogeniska frysar, kryogeniska dewarer och tillhörande tillbehör inom life science-industrin genom direktförsäljning eller ett distributionsnätverk.
Cryoport, Inc. Sammanfattning av grunderna
| CYRX grundläggande statistik | |
|---|---|
| Börsvärde | US$867.62m |
| Vinst(TTM) | -US$40.90m |
| Intäkter(TTM) | US$186.45m |
4.7x
P/S-förhållande-21.2x
P/E-förhållandeÄr CYRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CYRX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$186.45m |
| Kostnad för intäkter | US$98.68m |
| Bruttovinst | US$87.77m |
| Övriga kostnader | US$128.68m |
| Intäkter | -US$40.90m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.81 |
| Bruttomarginal | 47.08% |
| Nettovinstmarginal | -21.94% |
| Skuld/egenkapitalförhållande | 38.1% |
Hur har CYRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/24 15:40 |
| Aktiekurs vid dagens slut | 2026/08/21 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cryoport, Inc. bevakas av 14 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |